Fidaxomicin is an antibacterial drug in clinical use in treatment of Clostridium difficile diarrhea 1-2 .
Mycobacterium-specific sequence insertion 15 (β′MtbSI or "gate"), for σ conserved regions 2, 3, and 4 (σR2, σR3, and σR4), and for Lpm. The mean resolution of the structure is 3.5 Å (Extended Data Fig. 1e ).
Local resolution ranges from ~2.5-3.8 Å in central parts of the structure, including RNAP residues close to Lpm, to ~5-6.5 Å in peripheral parts of the structure, including β′MtbSI and σR4 ( Fig. 1a ; Extended Data Figs. 1f, 2a ). Local B-factors range from ~0-100 Å 2 in central regions to ~300-400 Å 2 in peripheral regions (Extended Data Fig. 2b ). Density maps show clear density for backbone and sidechain atoms of RNAP and individual functional groups of Lpm (Extended Data Fig. 2c-d) .
The cryo-EM structure shows that the Lpm binding site is located at the base of the RNAP clamp 14, [16] [17] and encompasses RNAP clamp α-helices βa16α1 and β′a4α1 and RNAP switch-region switches SW2, SW3, and SW4 5, 17 (Fig. 1 ; Extended Data Fig. 3 ). Lpm binds to RNAP in a fully-extended conformation similar to conformations in crystal structures of Lpm alone (Extended Data Fig. 3a ). All five structural moieties of Lpm--isobutyryl, β-D-noviosyl, macrocycle, β-D-rhamnosyl, and homodichloro-orsellinyl--interact with RNAP ( Fig. 1d-e ; Extended Data Figs. 1a, 3b-c). Lpm makes H-bonds with six RNAP residues: βT1096 (V1298), βK1101 (K1303), β′R84 (Q94), β′R89 (R99), β′E323 (D248), and β′R412 (R337) (residues numbered as in Mtb RNAP and, in parentheses, as in Escherichia coli RNAP). Alanine substitutions of these RNAP residues results in Lpm-resistance, confirming the interactions are functionally relevant (Extended Data Fig. 3d ).
Sequence alignments show that residues of RNAP that contact Lpm are conserved in Gram-positive and Gram-negative bacterial RNAP, but are not conserved in human RNAP I, II, and III (Extended Data Fig. 4a-b) , accounting for the ability of Lpm to inhibit both Gram-positive and Gramnegative bacterial RNAP but not human RNAP I, II, and III (Extended Data Fig. 4c ).
The cryo-EM structure accounts for structure-activity relationships of Lpm analogs produced by metabolism 18 , precursor feeding 19 , mutasynthesis [20] [21] , and semi-synthesis ( Fig. 1d 3b-c, 5). The structure accounts for structure-activity relationships indicating functional importance of the Lpm isobutyryl moiety (b1 vs. Lpm), β-D-noviosyl moiety (c1 vs. b2 and a6); macrocycle and C25 hydroxyl therein (a5 vs. Lpm), β-D-rhamnosyl moiety and C6' methyl therein (e1 vs. d1 and a7; a6 vs. Lpm), and homodichloro-orsellinyl moiety and C8" methyl, C3" chlorine, and C5" chlorine therein (d1 vs. Lpm; a2-a4 vs. Lpm; a8 vs. a6). The observation that the Lpm C4" hydroxyl is exposed to solvent at the exterior of RNAP (Extended Data Fig. 3b -c) predicts that substituents--including large substituents-may be introduced at the C4" hydroxyl oxygen without eliminating ability to inhibit RNAP, provided the H-bond-acceptor character of the oxygen is maintained. Validating this prediction, we have prepared a novel Lpm analog having benzyl appended at the C4" hydroxyl oxygen by semi-synthesis from Lpm and have found the analog to retain high activity in inhibiting RNAP (Extended Data Fig. 5, analog a1 ).
The binding site on RNAP for Lpm (cyan in Fig. 2a ) does not overlap the binding sites of other RNAP inhibitors, including rifampin and sorangicin 22-23 (Rif and Sor); GE23077 and pseudoridimycin [24] [25] (GE and PUM), CBR703 and D-AAP-1 15, [26] [27] (CBR and AAP), salinamide 28 (Sal), streptolydigin [29] [30] (Stl), and myxopyronin, corallopyronin, ripostatin, and squaramide 31-33 (Myx, Cor, Rip, and SQ) ( Fig. 2a ). The binding site for Lpm is close to, but does not overlap, the binding site of Myx, Cor, Rip and SQ, which bind to the RNAP switch region, contacting SW1 and the face of SW2 opposite the face contacted by Lpm. The binding site for Lpm is far from the binding sites of other RNAP inhibitors.
Amino acid substitutions conferring resistance to Lpm were identified by sequencing spontaneous Bacillus subtilis Lpm-resistant mutants 7, 9 ; additional substitutions were identified by sequencing induced Lpm-resistant mutants of E. coli RNAP 9 ; and, in this work, a full set of substitutions was identified by extending the latter method ( Fig. 2b-c) . Lpm-resistant substitutions are obtained at ten sites in RNAP β subunit and seven sites in RNAP β′ subunit (Fig 2b-c) . All sites of Lpm-resistant substitutions are located in the immediate vicinity of the Lpm binding site (Fig. 2b) , and all high-level (≥4-fold) Lpm-resistant substitutions involve RNAP residues that make direct contact with Lpm or that contact other RNAP residues that, in turn, make direct contact with Lpm (Extended Data Fig. 5a ). The resistance determinant for Lpm does not overlap the resistance determinants of other RNAP inhibitors (Fig. 2b) . Consistent with the absence of overlap of binding sites and resistance determinants, mutants resistant to Lpm are not cross-resistant to other RNAP inhibitors ( Fig. 2d; Extended Data Fig. 6b) , and, reciprocally, mutants resistant to other RNAP inhibitors are not cross-resistant to Lpm ( Fig. 2e; Extended Data Fig. 6c ). Further consistent with the absence of overlap of binding sites and resistance determinants, Lpm and Rif exhibit additive antibacterial activity when co-administered ( Fig. 2f ).
The RNAP clamp adopts different conformations--ranging from open, to partly closed, to closed-in different crystal structures 14, [16] [17] (Fig. 3a) . Differences in clamp conformation arise from rigid-body rotations about a hinge formed by the RNAP switch region 14, [16] [17] . Importantly, differences in clamp conformation are observed even in crystal structures of RNAP from a single bacterial species ( Fig. 3a ; 14 ; in contrast, Myx, Cor and Rip, through interactions with SW1 and the opposite face of SW2, trap a closed-clamp state (Fig . 3 ). The different effects of these inhibitors on RNAP clamp conformation presumably underlie their different effects on isomerization of RPc to RPo (inhibition of an early step in isomerization by Lpm; inhibition of a later step in isomerization by Myx, Cor, and Rip [10] [11] ).
The binding site on RNAP for Lpm overlaps the proposed binding site on RNAP for pause-inducing and termination-inducing RNA hairpins 34 . It is attractive to speculate that the Lpm binding site is an "allosteric trigger" for RNAP clamp opening and that ligands of this site--including not only Lpm but also pause-inducing and termination-inducing RNA hairpins--trigger RNAP clamp opening by binding to the site.
The effects of Lpm on RNAP clamp conformation suggest a model for the mechanism by which Lpm inhibits isomerization of RPc to RPo [8] [9] [10] [11] in transcription initiation ( Fig. 4 ). Because σR2 (the σ module that recognizes promoter -10 elements 35-39 ) interacts with the RNAP clamp and σR4 (the σ module that recognizes promoter -35 elements 35,37-39 ) interacts with the main mass of RNAP, differences in RNAP clamp conformation necessarily result in differences in the spatial relationship of σR2 and σR4 ( Fig. 4 , left panels). We propose that, in the closed-clamp state, σR2 and σR4 can engage simultaneously with promoter -10 and -35 elements (Fig. 4a , middle and right panels), but, in the open-clamp state, σR2 and σR4 cannot engage simultaneously with promoter -10 and -35 elements (Fig. 4b , middle and right panels). In particular, we propose that the σR2 "Trp wedge," which intercalates into DNA and stacks on the non-template-strand nucleotide at promoter position -12, nucleating promoter unwinding in formation of RPo 38-39 , can engage DNA only in the closed-clamp state, and that the σR2 "NT-11 pocket," which captures an unstacked non-template-strand nucleotide at promoter position -11, stabilizing promoter unwinding upon formation of RPo 36-39 , can engage DNA only in the closed-clamp state ( The methods and results of this report provide a strategy to obtain structural information for any RNAP inhibitor, irrespective of species selectivity and effects on RNAP conformation. The use of cryo-EM to determine the structure of RNAP-Lpm overcame obstacles that had precluded structure determination by x-ray crystallography: (1) the species selectivity of Lpm (which does not inhibit The results of this report provide fundamental information on the binding site and mechanism of Lpm and provide insights for antibacterial drug development involving Lpm. The primary limitation of Lpm as an antibacterial drug is that Lpm has no systemic bioavailability and thus is ineffective against systemic infections, such as tuberculosis and S. aureus blood and lung infections 1,2,5 . The chemical strategy and synthetic procedure demonstrated here for appending substituents at the Lpm C4" hydroxyl ( Fig S5; a1 ) provides a means to overcome this limitation. It should be possible to append substituents improving physical and pharmacokinetic properties, nanoparticle drug-delivery modules, or even other antibacterial-agent pharmacophores at the Lpm C4" hydroxyl while retaining RNAP-inhibitory activity.
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METHODS

Lpm
Lpm was the kind gift of A.L. Sonenschein (Tufts University, Medford MA), was prepared as described 41 , or was purchased from BioAustralis or Biorbyt.
Lpm analogs: previously described Lpm analogs
Lpm analog "a4" (3"-bromo-3",5"-dideschloro-Lpm; compound 3 of ref. 19 ) was prepared as described 19 . Lpm analogs "a5" (69-1d), "a6" (70-9d), "a7" (70-10d), "a8" (70-11d), "b2" (53-11d), "c1" (54-4d), and "e1" (54-3d) were prepared as described [20] [21] . Lpm analog "b1" (OP-1118 18 ) was purchased from Toronto Research Chemicals.
Lpm analogs: Lpm analogs "a2" (5"-deschloro-Lpm) and "d1" (desaryl-Lpm)
Lpm analogs "a2" (5"-deschloro-Lpm) and "d1" (desaryl-Lpm) were prepared by fermentation of the Lpm producer strain Dactylosporangium aurantiacum hamdenensis NRRL 18085 42 (ARS Patent Culture Collection, Peoria IL) in growth media containing limiting chloride [growth media with KCl replaced by KBr; residual chloride concentration = 40 μM, quantified using QuantiChromT Chloride Assay Kit (BioAssays Systems)]. First-stage (0.2 L) and second-stage (10 L) cultures were prepared as described 19 , and second-stage culture broths were harvested as described 19 . Culture broths were adjusted to pH 7 by addition of 1 ml 12 N NaOH, supplemented with 5 L acetone, shaken 1 h at 22°C, and extracted with 3x4 L ethyl acetate. The extracts were evaporated, and the resulting material (20 g) was re-dissolved in 300 ml ethyl acetate, filtered through Whatman #1 filter paper (Sigma-Aldrich), and evaporated. The resulting material (14 g) was partitioned in 900 ml 1:1:1 (v/v/v) chloroformmethanol-water, and the lower phase was evaporated. The resulting material (11 g) was chromatographed on silica gel (Sigma-Aldrich; 3 cm x 30 cm; stepwise elution with 2-50% methanol in chloroform, followed by elution with 100% methanol). UV-absorbant (254 nm) fractions were collected, evaporated, and assayed for antibacterial activity by spotting on H-top-agar/LB-agar 43 plates seeded with 10 9 cfu E. coli D21f2tolC 44 , incubating 16 h at 37, and assessing growth inhibition. Active fractions eluting at ~5% to ~10% methanol were pooled, further purified by re-chromatography on silica gel 
Lpm analogs: Lpm analog "a1" (4"-O-benzyl-Lpm)
Lpm analog "a1" (4"-O-benzyl-Lpm) was prepared from Lpm by semi-synthesis as follows: To Lpm (Biorbyt: 3 mg; 2.8 μmol) in 50 μl anhydrous dimethylformamide (Sigma-Aldrich), was added anhydrous potassium carbonate (Thermo-Fisher: 3 mg, 22 μmol), and the reaction mixture was stirred 30 min at 50°C and then allowed to cool to room temperature. An aliquot (10 μl) of 0.28 M benzyl bromide in anhydrous dimethylformamide [2.8 μmol; prepared by dissolving 3.4 μl benzyl bromide (Sigma-Aldrich) in 50 μl anhydrous dimethylformamide immediately before use] was added, and the reaction mixture was stirred 30 min at 50°C. The reaction mixture was evaporated to remove dimethylformamide and then re-suspended in 600 μl 100 mM monobasic sodium phosphate (Thermo-Fisher). Precipitated solids were collected by centrifugation, rinsed with water, re-dissolved in methanol, and purified by reversed-phase HPLC (Phenomenex C18 Luna, 100 Å, 25 mm x 4.6 mm; phase A = water; phase B = acetonitrile; gradient = 40% B at 0 min, 100% B at 20 min; flow rate = 1 ml/min). Lpm analog "a1" eluted at 20 minutes. Yield: 0.35 mg, 10%. MALDI-MS m/z: calculated, 1171.44 (M + Na+); found 1169.64, 1171.64.
Other RNAP inhibitors
Cor A and Rip A were the kind gift of H. Irschik and R. Jansen (Helmholtz Institut, Braunschweig, Germany), Stl was the kind gift of E. Steinbrecher (Upjohn-Pharmacia, Kalamazoo, MI), and Sal A was the kind gift of W. Fenical (The Scripps Research Institute, La Jolla, CA). Myx B was prepared as described 45 , SQ1 (compound 1 of ref. 46 ) was prepared as described 46 , GE was prepared as described 47 , and PUM was prepared as described 25 . Rif was purchased from Sigma-Aldrich, and CBR was purchased from Maybridge.
M. tuberculosis RNAP σ A holoenzyme
For all experiments other than the experiments in Extended Data Fig. 3d , Mtb RNAP σ A holoenzyme was prepared as described 15 .
For experiments in in Extended Data Fig. 3d , Mtb RNAP σ A holoenzyme and Mtb RNAP σ A holoenzyme derivatives were prepared by the same procedure, but using plasmid pCOLADuet-Mtb-rpoBC [prepared by replacing the NcoI-BamHI segment of plasmid pCOLA-Duet (Novagen) by the NcoI-BamHI segment of a DNA fragment carrying CCATGGTG followed by Mtb rpoB codons 3-1174 followed by TAAGGATCC, prepared by PCR using as template plasmid JF09 48 (gift of S. Rodrigue, Universitė de Sherbrooke, Canada), and then replacing the NdeI-MfeI segment of the resulting plasmid by the NdeI-MfeI segment of a DNA fragment carrying CATATG followed by Mtb rpoC codons 2-1316 followed by TAGCAATTG, prepared by PCR using as template plasmid JF10 48 (gift of S. Rodrigue, Universitė de Sherbrooke, Canada)], or derivatives thereof constructed using site-directed mutagenesis (QuikChange Site-Directed Mutagenesis Kit; Agilent), in place of plasmid pCOLA-rpoB-rpoC 49 .
S. aureus RNAP σ A holoenzyme
S. aureus RNAP σ A holoenzyme was prepared as described 25 .
E. coli RNAP σ 70 holoenzyme
For experiments in Extended Data Fig. 5 , hexahistidine-tagged E. coli RNAP σ 70 holoenzyme was prepared from E. coli strain XE54 50 transformed with plasmid pREII-NHα 50 , using procedures as described 51 For experiments in Figs. 3c-e and Extended Data Fig. 8c-d , fluorescent-probe-labelled, hexahistidine-tagged E. coli RNAP σ 70 holoenzyme was prepared using unnatural-amino-acid mutagenesis 14,52 of co-expressed genes encoding RNAP β', β, α, and ω subunits and σ 70 , yielding an RNAP σ 70 holoenzyme derivative containing 4-azido-L-phenylalanine (AzF) at position 284 of β' and position 106 of β, followed by azide-specific Staudinger ligation 14, [53] [54] [55] to incorporate the fluorescent probes Cy3B and Alexa647 at position 284 of β' and position 106 of β, as follows (Extended Data Fig.  8a ): Single colonies of E. coli strain BL21(DE3) (Millipore) co-transformed with plasmid pVS10-rpoB106am;rpoC284am [constructed by use of site-directed mutagenesis (QuikChange Site-Directed Mutagenesis Kit; Agilent) to replace rpoB codon 106 and rpoC codon 284 by amber codons in plasmid pVS10 56 ], plasmid pRSFsigma70 57 , and plasmid pEVOL-pAzF 52 were used to inoculate 20 ml LB broth 43 containing 100 μg/ml ampicillin, 50 μg/ml kanamycin, and 35 μg/ml chloramphenicol, and cultures were incubated 16 h at 37°C with shaking. Culture aliquots (2x10 ml) were used to inoculate LB broth 43 (2x1 L) containing 2 mM AzF (Chem-Impex International), 100 μg/ml ampicillin, 50 μg/ml kanamycin, and 35 μg/ml chloramphenicol, cultures were incubated with shaking until OD 600 = 0.6; L-arabinose was added to 0.2% and IPTG was added to 1 mM, and cultures were further incubated 16 h at 16°C with shaking. Cells were harvested by centrifugation (4,000 x g; 20 min at 4˚C), re-suspended in 20 ml buffer A (10 mM Tris-HCl, pH 7.9, 200 mM NaCl, and 5% glycerol), and lysed using an EmulsiFlex-C5 cell disrupter (Avestin). The lysate was cleared by centrifugation (20,000 x g; 30 min at 4°C), precipitated with polymin P (Sigma-Aldrich) as described 51 , and precipitated with ammonium sulfate as described 51 . The sample was dissolved in 30 ml buffer A and loaded onto a 5 ml column of Ni-NTA-agarose (Qiagen) pre-equilibrated in buffer A, and the column was washed with 50 ml buffer A containing 10 mM imidazole and eluted with 25 ml buffer A containing 200 mM imidazole. The sample was further purified by anion-exchange chromatography on Mono Q 10/100 GL (GE Healthcare; 160 ml linear gradient of 300-500 mM NaCl in 10 mM Tris-HCl, pH 7.9, 0.1 mM EDTA, and 5% glycerol; flow rate = 2 ml/min). Fractions containing AzF-derivatized hexahistidine-tagged E. coli RNAP σ 70 holoenzyme were pooled, concentrated to ~1 mg/ml using 30 kDa MWCO Amicon Ultra-15 centrifugal ultrafilters (Millipore), and stored in aliquots at -80°C. A reaction mixture containing 10 μM AzF-derivatized hexahistidine-tagged E. coli RNAP σ 70 holoenzyme, 100 μM Alexa647-pentanoylethylenediaminyl-phosphine (prepared as described [54] [55] ), and 100 μM Cy3B-carboyl-ethylenediaminylphosphine (prepared as described`5 4-55 ) in 1 ml buffer B (50 mM Tris-HCl, pH 7.9, 100 mM KCl, 5% glycerol, and 2% dimethylformamide) was incubated 1 h at 15°C, incubated 16 h on ice, and subjected to 5 cycles of buffer exchange (dilution with 5 ml buffer B, followed by concentration to 0.5 ml) using 30 kDa MWCO Amicon Ultra-15 centrifugal ultrafilters (Millipore). The sample was further purified by gel-filtration chromatography on HiLoad 16/60 Superdex 200 prep grade (GE Healthcare) pre-equilibrated in buffer C (20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 5 mM MgCl2, 1 mM β-mercaptoethanol, and 5% glycerol) and eluted in buffer C. Fractions containing fluorescent-probelabelled hexahistidine-tagged E. coli RNAP σ 70 holoenzyme were pooled, concentrated to 1 mg/ml in buffer C using 30 kDa MWCO Amicon Ultra-15 centrifugal ultrafilters (Millipore) and stored in aliquots at -80°C.
For experiments in Fig. 3f , fluorescent-probe-labelled, hexahistidine-tagged, FLAG-tagged E. coli RNAP σ 70 holoenzyme was prepared using unnatural-amino-acid mutagenesis 52 where A 280 is the measured absorbance at 280 nm, A Cy3B,559 is the measured absorbance at the long-wavelength absorbance maximum of Cy3B (559 nm), A Alexa,652 is the measured absorbance at the long-wavelength absorbance maximum of Alexa647 (652 nm), ε P,280 is the molar extinction coefficient of RNAP σ 70 holoenzyme at 280 nm (240,000 M -1 cm -1 ), ε Cy3B,280 is the molar extinction coefficient of Cy3B at 280 nm (7,350 M -1 cm -1 ), ε Alexa,280 is the molar extinction coefficient of Alexa647 at 280 nm (10,400 M -1 cm -1 ), and ε Cy3B,559 is the extinction coefficient of Cy3B at its long-wavelength absorbance maximum (130,000 M -1 cm -1 ), and ε Alexa,652 is the extinction coefficient of Alexa647 at its long-wavelength absorbance maximum (245,000 M -1 cm -1 ). Labelling efficiencies were ~90% for Cy3B and ~70% for Alexa647.
Specificities of incorporation of fluorescent probes were determined from the observed labelling efficiencies of (i) the labelling reaction with the AzF-derivatized hexahistidine-tagged E. coli RNAP σ 70 where AzF-P is AzF-derivatized hexahistidine-tagged E. coli RNAP σ 70 holoenzyme, and P is non-AzF-derivatized hexahistidine-tagged E. coli RNAP σ 70 holoenzyme. Labelling specificities were >90%.
T. thermophilus RNAP core enzyme T. thermophilus RNAP core enzyme was prepared as described 36 .
RNAP-inhibitory activities
Fluorescence-detected RNAP-inhibition assays with the profluorescent substrate γ-[2′-(2benzothiazoyl)-60-hydroxybenzothiazole]-ATP (BBT-ATP; Jena Bioscience) were perfomed as described 32 , using 75 nM RNA holoenzyme (Mtb RNAP σ A holoenzyme or derivative, S. aureus σ A RNAP holoenzyme, or E. coli RNAP σ 70 holoenzyme) and 20 nM DNA fragment containing bacteriophage T5 N25 promoter (prepared as described 24 ).
Radichemical RNAP-inhibition assays with HeLa nuclear extract (human RNAP I/II/III) were performed as described 28.
Half-maximal inhibitory concentrations (IC50s) were calculated by non-linear regression in SigmaPlot (Systat Software).
Lpm-resistant mutants
Lpm-resistant mutants were isolated using procedures analogous to those used for isolation of Myx-resistant mutants in ref. 31. Random mutagenesis of E. coli rpoC plasmid pRL663 59 and E. coli rpoB plasmid pRL706 60 all other components at concentrations as specified by the manufacturer). Mutagenized plasmid DNA was introduced by transformation into E. coli XL1-Blue (Agilent). Transformants (~10 4 cells) were applied to LB-agar 43 plates containing 200 μg/ml ampicillin, plates were incubated 16 h at 37°C, and plasmid DNA was prepared from the pooled resulting colonies. The resulting pooled mutagenized plasmid DNA was introduced by transformation into uptakeproficient, efflux-deficient E. coli strain D21f2tolC 44 . Transformants (~10 3 cells) were applied to LB-agar 43 plates containing 5 μg/ml Lpm (the minimal concentration that prevents colony formation by wild-type transformants), 200 μg/ml ampicillin, and 1 mM IPTG, and plates were incubated 24-48 h at 37°C. Lpm-resistant mutants were identified by the ability to form colonies on this medium, were confirmed by re-streaking on the same medium, and were demonstrated to contain plasmid-linked Lpmresistant mutations by preparing plasmid DNA, transforming E. coli D21f2tolC with plasmid DNA, and plating transformants on the same medium. Nucleotide sequences of rpoB and rpoC were determined by Sanger sequencing (nine primers per gene).
Resistance and cross-resistance levels
Experiments in Fig. 2c and Extended Data Fig. 6b-c 43 containing 200 μg/ml ampicillin and incubated at 37°C with shaking until OD 600 = 0.4-0.6, IPTG was added to 1 mM, and cultures were incubated 1 h at 37°C with shaking. Diluted aliquots (~1x10 9 cfu/ml for Fig. 2c and ~1x10 8 cfu/ml for Extended Data Fig. 6b ) were swabbed radially onto plates, and plates were incubated 16 h at 37°C. For each culture, the streak length was measured using a clear plastic template (Spiral Biotech), the test-compound concentration at the streak endpoint was calculated using the program SGE (Spiral Biotech), and the minimum inhibitory concentration (MIC) was defined as the test-compound concentration at the streak endpoint.
Experiments in Fig. 2d assessing resistance and cross-resistance levels of chromosomal Lpm-resistant mutants [mutations transferred from pRL706 or pRL663 derivatives of preceding section to chromosome of E. coli D21f2tolC 44 by λ-Red-mediated recombineering (procedures essentially as described 64 , but using transformation rather than electroporation)] were performed using broth microdilution assays 65 . Single colonies were inoculated into 5 ml LB broth 43 and incubated at 37°C with shaking until OD 600 = 0.4-0.8. Diluted aliquots (~5x10 4 cells) in 97 μl LB broth were dispensed into wells of a 96-well plate, and were supplemented with 3 μl methanol or 3 μl of a 2-fold dilution series of Lpm (MIC wild-type = 1.56 μg/ml), Rif (MIC wild-type = 0.20 μg/ml), CBR (MIC wild-type = 6.25 μg/ml), Sal (MIC wildtype = 0.049 μg/ml), Stl (MIC wild-type = 3.13 μg/ml), or Myx (MIC wild-type = 0.20 μg/ml), in methanol (final concentrations = 0 and 0.006-50 μg/ml), or diluted aliquots (~1x10 5 cells) in 50 μl LB broth were supplemented with 50 μl LB broth or 50 μl of a 2-fold dilution series of GE (MIC wild-type = 500 μg/ml) or PUM (MIC wild-type = 400 μg/ml) in LB broth (final concentrations = 0 and 25-2000 μg/ml). Plates were incubated 16 h at 37°C. The MIC was defined as the lowest tested concentration that inhibited bacterial growth by ≥90%.
Experiments in Fig. 2e assessing Lpm-cross-resistance levels of Rif-, GE/PUM-, and Sal-resistant mutants were performed as described for experiments in Fig. 2d , but analyzing a panel of E. coli D21f2tolC derivatives 25,28 comprising 4 chromosomal Rif-resistant mutants, 3 chromosomal GE/PUM-resistant mutants, and 5 chromosomal Sal-resistant mutants.
Experiments in Fig. 2e assessing Lpm-cross-resistance levels of CBR-and Stl-resistant mutants were performed essentially as described for experiments in Fig. 2d , but analyzing a panel of E. coli D21f2tolC pRL706 and E. coli D21f2tolC pRL663 derivatives 26,29 comprising 5 CBR-resistant mutants and 5 Stl-resistant mutants. Single colonies were inoculated into 5 ml LB broth 43 containing 200 μg/ml ampicillin and incubated at 37°C with shaking until OD 600 = 0.4-0.6, IPTG was added to 1 mM, and cultures were incubated 1 h at 37°C with shaking. Diluted aliquots (~5x10 4 cells) in 97 μl LB broth containing 200 μg/ml ampicillin and 1 mM IPTG were dispensed into wells of a 96-well plate, and were supplemented with 3 μl methanol or 3 μl of a 2-fold dilution series of CBR or Stl in methanol and further processed as described for experiments in Fig. 2d .
Checkerboard interaction assays
Antibacterial activities of combinations of Lpm and Rif were assessed in checkerboard interaction assays [70] [71] . Broth-macrodilution (procedures essentially as described 65 ) were performed in checkerboard format, using E. coli D21f2tolC 44 and using LB broth 43 containing pairwise combinations of: (i) Lpm at 2.0x, 1.75x, 1.5x, 1.3125x, 1.25x, 1.125x, 0.9375x, 0.75x, 0.5625x, 0.5x, 0.375x, 0.25x, and 0.1875x MIC Lpm and (ii) Rif at 2.0x, 1.75x, 1.5x, 1.3125x, 1.25x, 1.125x, 0.9375x, 0.75x, 0.5625x, 0.5x, 0.375x, 0.25x, and 0.1875x MIC Rif . Fractional inhibitory concentrations (FICs), FIC indices (FICIs), and minimum and maximum FICIs (FICI min and FICI max ) were calculated as described 71 . FICI min ≤ 0.5 was deemed indicative of super-additivity (synergism), FICI min > 0.5 and FICI max ≤ 4.0 was deemed indicative of additivity, and FICI max > 4.0 was deemed indicative of sub-additivity (antagonism) [70] [71] .
Cryo-EM structure determination (M. tuberculosis RNAP-Lpm): sample preparation
Lacey carbon grids (LC300-CU-100; Electron Microscopy Sciences) were glow-discharged for 30 s using a glow-discharge cleaning system (PELCO easiGlow; Ted Pella) and mounted in the sample chamber of an EM GP grid plunger (Leica) at 18ºC and relative humidity = 95%. Grids were spotted with 3.5 µl 1 μM Mtb RNAP-Lpm and 50 μM Lpm in 20 mM Tris-HCl, pH 8.0, 75 mM NaCl, 5 mM MgCl 2 , 5 mM dithiothreitol, and 0.1% n-octyl-β-D-glucopyranoside [prepared by pre-equilibrating 150 μl samples containing components other than n-octyl-β-D-glucopyranoside (Biosynth) 30 min at 25°C, and adding n-octyl-β-D-glucopyranoside immediately before spotting], incubated 10 s, blotted with filter paper (Whatman Grade 541; Sigma-Aldrich) for 2.3 s, flash-frozen by plunging in liquid ethane cooled with liquid nitrogen, and stored in liquid nitrogen.
Cryo-EM structure determination (M. tuberculosis RNAP-Lpm): data collection and data reduction
Data were collected at the National Resource for Automated Molecular Microscopy of the Simons Electron Microscopy Center using a 300 keV Titan Krios (FEI/ThermoFisher) electron microscope equipped with a K2 Summit direct electron detector (Gatan) operating in counting mode and a GIF Quantum energy filter (Gatan) with slit width of 20 eV. Data were collected semi-automatically using the software package Leginon 72 , a nominal magnification of 130,000x, a calibrated pixel size of 1.061 Å, and a dose rate of 8 electrons/pixel/s. Movies were recorded at 200 ms/frame for 10 s (50 frames total), resulting in a total radiation dose of 72.05 electrons/Å 2 per movie Defocus range was varied between 1.0 µm and 2.0 µm. A total of 2,458 micrographs were recorded from two grids over 2 days.
Data were processed as summarized in Extended Data Fig. 1b-d . Data processing was performed on an Ubuntu 16.04 Linux GPU workstation (Titan Computers) containing four GTX 1080 Ti graphic cards (Nvidia) 73 . Frames in individual movies were aligned using MotionCor2 74 , and the first 35 frames per movie were merged to calculate individual micrographs. Contrast-transfer-function estimations were performed using Gctf 75 , yielding defocus-range estimates ranging from 0.4 μm to 4.0 µm for individual micrographs. Initial particle picking was performed on 25 selected micrographs from the first grid (8,609 particles) using the Xmipp routine of the software package Scipion v1.1 76 , and particles were used for two-dimensional class averaging in Relion v2.0.5 77 . Eight distinct two-dimensional classes were selected as templates for picking 452,912 particles from 1,236 selected micrographs from the first grid and 366,594 particles from 1,025 selected micrographs from the second grid, using the Autopick routine of Relion. Two-and three-dimensional classifications were performed on the 452,912 particles from the first grid and 366,594 particles from the second grid, using Relion and using a 60 Å low-pass-filtered map calculated from the crystal structure of Mtb RPo (PDB 5UH5 15 ; protein residues only) as the starting reference model for three-dimensional classification. Following identification and removal of heterogeneous particles in the two-and three-dimensional classifications, independent but similar density maps were obtained from 126,977 particles from the first grid and 97,412 particles from the second grid. Following merging of the 224,389 particles from the first and second grids, three-dimensional auto-refinement using Relion, and local angular sampling using Relion, a final density map was obtained from a subset of 68,895 particles. Gold-standard Fourier-shell-correlation analysis (FSC 78 ) indicated a mean map resolution of 3.52 Å, and ResMap 79 indicated a median map resolution of 3.5 Å (Extended Data Fig. 1e-f ; Extended Data Table 1 ). The initial atomic model for protein residues of Mtb RNAP-Lpm was built by manual rigid-body fitting of RNAP β', RNAP β, RNAP α I, , RNAP α II , RNAP ω , and σ segments from the crystal structure of Mtb RPo (PDB 5UH5 15 ; protein residues only) into the cryo-EM density map in Coot ??80 , followed by adjustment of backbone and sidechain conformations in Coot. For σR4 (residues 464-528), density was weak, suggesting high segmental flexibility; σR4 was fitted as a rigid-body segment and was not further adjusted. For the RNAP β' N and C-termini (residues 1-2 and 1282-1316), the central part of the RNAP β' trigger loop (residues 1014-1022), the RNAP β N and C-termini (residues 1-27 and 1145-1172), the RNAP α I N-terminus and C-terminal domain (residues 1-2 and 227-347), the RNAP α II N-terminus and C-terminal domain (residues 1-2 and 233-347), the RNAP ω N-terminus (residues 1-27), σR1.1 (residues 1-224), and a loop and short extended segment of the σR3-σR4 linker (residues 426-433 and 443-445), density was absent, suggesting very high segmental flexibility; these segments were not fitted. The initial atomic model for Lpm atoms of Mtb RNAP-Lpm was built by manual rigid-body fitting of a crystal structure of Lpm (CCDC 114782 81 ) into the cryo-EM density map using Coot 80 , followed by torsionangle adjustments using Coot. Iterative cycles were performed of real-space model building in Coot 80 followed by reciprocal-space fitting to structure-factor amplitudes and phases calculated from the cryo-EM density map in Phenix 82 . The final atomic model, with map-to-model correlation of 0.83, was deposited in the Electron Microscopy Data Bank (EMDB) and Protein Data Bank (PDB) with accession codes EMDB 4230 and PDB 6FBV (Extended Data Table 1 ).
Crystal structure determination (T. thermophilus RNAP core enzyme): sample preparation
Robotic crystallization trials were performed for T. thermophilus RNAP core enzyme using a Gryphon liquid handling system (Art Robbins Instruments, Inc.), commercial screening solutions (Emerald Biosystems, Hampton Research, and Qiagen), and the sitting-drop vapor-diffusion technique (drop: 0.2 µl RNAP plus 0.2 µl screening solution; reservoir: 60 µl screening solution; 22°C). 900 conditions were screened. Rod-like crystals appeared under the identified crystallization conditions [0.1 M Hepes-NaOH, pH 7.5, 20 mM MgCl 2 , and 22% poly(acrylic acid sodium salt), 5,100 Da (Hampton Research); 22°C] within two weeks. Crystals were transferred from the sitting drop to a reservoir solution containing 20% (v/v) ethylene glycol (Sigma-Aldrich) and flash-cooled by immersing in liquid nitrogen.
Crystal structure determination (T. thermophilus core enzyme): data collection and data reduction
Diffraction data and selenium single-wavelength anomalous dispersion data were collected from cryo-cooled crystals at Argonne Photon Source beamline 19ID-D. Data were processed using HKL2000 83 . The resolution cut-off criteria were I/σ > 1.1 and R merge < 1.
The structure of T. thermophilus RNAP core was solved by molecular replacement with Molrep 84 using PDB 4GZY 85 as the search model. One RNAP molecule was present in the asymmetric unit. Early-stage refinement included rigid-body refinement of RNAP, followed by rigid-body refinement of RNAP subunits, followed by rigid-body refinement of 44 RNAP domains (methods as described 36 ). Cycles of iterative model building with Coot 80 and refinement with Phenix 82 were performed. Improvement of the coordinate model resulted from improvement of phasing. The final model was generated by XYZ-coordinate refinement with secondary-structure restraints in Phenix, followed by group B-factor and individual B-factor refinement in Phenix. The final model, refined to R work and R free of 0.22 and 0.27, respectively, was deposited in the PDB with accession code PDB 6ASG (Extended Data Table 2 ).
Single-molecule FRET: sample preparation
Observation wells were prepared essentially as described [86] [87] (Extended Data Fig. 8b ): Borosilicate glass coverslips (#1.5; Menzel Gläzer) were incubated in 40 ml acetone 5 min at 22°C, incubated in 40 ml 2% (v/v) Vectabond aminosilane reagent (Vector Labs) in acetone 5 min at 22°C, washed with 100 ml water at 22°C, dried under nitrogen, and bonded to CultureWell 6 mm silicone gaskets (GBL103280; Grace Bio-labs), yielding 30 μl wells containing aminosilane-functionalized glass floors. Aliquots (20 μl ) of 30 mM methoxy-PEG succinimidyl valerate (mPEG-SVA, MW 5,000; Laysan Bio) and 0.75 mM biotinyl-PEG succinimidyl valerate (Biotin-PEG-SVA, MW 5,000; Laysan Bio) in 50 mM MOPS-NaOH, pH 7.5, were added to wells and incubated 90 min at 22°C, supernatants were removed, and wells were washed with 5x200 μl PBS (0.01 M sodium phosphate, pH. 7.4, 137 mM NaCl, and 2.7 mM KC), yielding wells with biotin-PEG/mPEG-functionalized borosilicate glass floors. Aliquots (30 μl) of 10 μM Neutravidin (Sigma Aldrich) in 0.5xPBS then were added to wells and incubated 10 min at 22°C, supernatants were removed, and wells were washed with 3x100 μl PBS, yielding wells with Neutravidin-biotin-PEG/PEG-functionalized glass floors. Aliquots (30 μl) of 40 nM biotinylated anti-hexahistidine monoclonal antibody (Penta-His Biotin Conjugate; Qiagen) in buffer KG7 (40 mM Hepes-NaOH, pH 7.0, 100 mM potassium glutamate, 10 mM MgCl 2 , 1 mM dithiothreitol, 100 μg/ml bovine serum albumin, and 5% glycerol) then were added to wells and incubated 10 min at 22°C, supernatants were removed, and wells were washed with 3x100 μl KG7, yielding wells with (biotinylated anti-hexahistidine monoclonal antibody)-Neutravidin-biotin-PEG/mPEG-functionalized glass floors.
For experiments in Fig. 3c -e and Extended Data Fig. 8c-d For experiments in Fig. 3f , fluorescent-probe-labelled, hexahistidine-tagged E. coli RNAP σ 70 holoenzyme was immobilized in observation wells containing (biotinylated anti-hexahistidine monoclonal antibody)-Neutravidin-biotin-PEG/mPEG-functionalized glass floors in the absence of Lpm as described above, and 3 μl 200 μM Lpm in the same buffer was added during data acquisition (Lpm final concentration = 20 μM).
Single-molecule FRET: data collection and data analysis
FRET experiments were performed on an objective-type total-internal-reflection (TIRF) microscope [86] [87] [88] . Light from a green laser (532 nm; Samba; Cobolt) and a red laser (635 nm; CUBE 635-30E; Coherent) was combined using a dichroic mirror, coupled into a fiber-optic cable, focused onto the rear focal plane of a 100x oil-immersion objective (numerical aperture 1.4; Olympus), and displaced off the optical axis such that the incident angle at the oil-glass interface of a stage-mounted observation chamber was greater than the critical angle, thereby creating an exponentially decaying evanescent wave. Alternating-laser excitation (ALEX 89 ) was implemented by directly modulating the two lasers using an acousto-optical modulator (1205C; Isomet). Fluorescence emission was collected from the objective, separated from excitation light by a dichroic mirror (545 nm/650 nm; Semrock) and emission filters (545 nm LP, Chroma; and 633/25 nm notch filter, Semrock), focussed on a slit to crop the image, and then spectrally separated using a dichroic mirror (630 nm DLRP; Omega) into donor and emission channels focused side-by-side onto an electron-multiplying charge-coupled device camera (EMCCD; iXon 897; Andor Technology). A motorized x/y-scanning stage with continuous reflective-interface feedback focus (MS-2000; ASI) was used to control the sample position relative to the objective.
For experiments in Fig. 3c-e and Extended Data Fig. 8c-d , laser powers were 3.5 mW (532 nm laser) and 0.7 mW (635 nm laser), and data were collected for 20 s using a frame rate of 1 frame per 20 ms. For experiments in Fig. 3f , laser powers were 0.5 mW (532 nm laser) and 0.15 mW (635 nm laser), and data were collected for 50 s using a frame rate of 200 ms.
Fluorescence emission intensities in donor (green) and acceptor (red) emission channels were detected using the peak-finding algorithm of the MATLAB (MathWorks) software package Twotone-ALEX 88 , as described 88 . Peaks detected in both emission channels (i.e., peaks for molecules containing both donor and acceptor probes) and meeting ellipticity and distance-to-nearest-neighbor thresholds (i.e., ellipticity ≤ 0.6 and distance-to-nearest-neighbor ≥ 6 pixels) were fitted with two-dimensional Gaussian functions to extract background-corrected intensity-vs.-time trajectories for donor emission intensity upon donor excitation (I DD ), acceptor emission intensity upon donor excitation (I DA ), and acceptor emission intensity upon acceptor excitation (I AA ) (Extended Data Fig. 8c, top) , as described 88 . Intensity-vs.-time trajectories were curated to exclude trajectories exhibiting I DD <300 or >2,000 counts or I AA <200 or >2,000 counts, trajectories exhibiting multiple-step donor or acceptor photobleaching, trajectories exhibiting donor or acceptor photobleaching in frames 1-50, and trajectories exhibiting donor or acceptor photoblinking, and to exclude portions of traces following donor or acceptor photobleaching.
Intensity-vs.-time trajectories were used to calculate trajectories of apparent donor-acceptor FRET efficiency (E*) and donor-acceptor stoichiometry (S) (Extended Data Fig. 8c, bottom) , as described [89] [90] : E*-vs.-S plots were prepared, S values were used to distinguish species containing only donor, only acceptor, and both donor and acceptor, and E* histograms were prepared for species containing both donor and acceptor, as described [89] [90] . E*-vs. time trajectories that on visual inspection exhibited transitions between distinct E* states (dynamic E*-vs.-time trajectories; ~34%; N = 207) were analyzed globally to identify E* states by use of Hidden Markov Modelling (HMM) with an empirical Bayesian as implemented in the MATLAB (MathWorks) software package ebFRET 91 , essentially as described [86] [87] 91 . E*-vs.-time trajectories were fitted to HMM models with two, three, four, five, or six distinct E* states; the mean scoring parameter L (lower bound per trajectory) was extracted for each model. and the model with three distinct E* states was found to best describe the data (Fig. 3c, right ; L = 536, 538, 537,537 and 537 for models with two, three, four, five, and six states). E* values from the three-state HMM model were extracted, plotted using Origin (OriginLab), and fitted to Gaussian distributions using Origin (Fig 3c, left, colored curves) . The resulting histograms provide equilibrium population distributions of E* states and, for each E* state, define mean E* (Fig 3c, left , colored curves and inset).
Dwell times for E* states were extracted from E*-vs.-time trajectories exhibiting >3 transitions between E* states and were plotted as histograms in Origin (Extended Data Fig. 8d ). The resulting dwelltime histograms were fit with single-exponential functions, and mean dwell times were extracted ( Fig. 3e ; Extended Data Fig. 8d ).
E* values were corrected, and accurate donor-acceptor efficiencies (E) and donor-acceptor distances (R) were calculated, as follows 90 . where, C 1 is "cross-talk" from leakage of donor emission into the acceptor-emission channel, C 2 is "cross-talk" from direct excitation of the acceptor by the green laser, γ is the detection factor (1 in this work; determined as γ = ΔI AA /ΔI DD , where ΔI AA and ΔI DD are changes in I AA and I DD upon acceptor photobleaching 92 ), E* DO is E* of the donor-only subpopulation, S AO is S of the acceptor-only subpopulation, and R 0 is the Főrster parameter [60.1 Å in this work; calculated as: R 0 = 9780(n -4 κ 2 Q D J) 1/6 Å, where n is the refractive index of the medium, κ 2 is the orientation factor relating donor emission dipole and acceptor excitation dipole (approximated as 2/3, noting that all mean E values are <0.5 93 ), Q D is the quantum yield of the donor in the absence of acceptor, and J is the overlap integral of donor emission spectrum and acceptor excitation spectrum]. RNAP clamp angles were determined from E values using the plot of RNAP clamp angle vs. E in Fig. 1 of ref. 14.
Data analysis
Data for RNAP-inhibitory activities, resistance, and cross-resistance are means of at least two technical replicates
Data availability
The cryo-EM map and atomic coordinates for the cryo-EM structure of Mtb RNAP-Lpm have been deposited in the EMDB and PDB with accession codes EMDB 4230 and PDB 6FBV. Atomic coordinates and structure factors for the crystal structure of T. thermophilus RNAP core enzyme have been deposited in the PDB with accession code PDB 6ASG. 
